Original article<br>Opioid agonist – tachykinin antagonist as a new analgesic with adjuvant anticancer properties

Joanna Matalińska; Henryk Skurzak; Sergiusz Markowicz; Anna Lesniak; Mariusz Sacharczuk; Gabriella Molnar; Eva Varga; Andrzej W. Lipkowski

doi:10.5114/fn.2013.35956

eISSN: 1509-572x
ISSN: 1641-4640

Folia Neuropathologica

Current issue Archive Manuscripts accepted About the journal Special Issues Editorial board Reviewers Abstracting and indexing Subscription Contact Instructions for authors Ethical standards and procedures

Editorial System

Submit your Manuscript

Editorial Policies

Sarajevo Declaration on Integrity and Visibility of Scholarly Publications

2/2013
vol. 51

Send email

Copy url:

abstract:

Original article
Opioid agonist – tachykinin antagonist as a new analgesic with adjuvant anticancer properties

Joanna Matalińska

,

Henryk Skurzak

,

Sergiusz Markowicz

,

Anna Lesniak

,

Mariusz Sacharczuk

,

Gabriella Molnar

,

Eva Varga

,

Andrzej W. Lipkowski

Folia Neuropathol 2013; 51 (2): 132-139

DOI: https://doi.org/10.5114/fn.2013.35956

Online publish date: 2013/06/26

View full text Get citation

PlumX metrics:

Opiate analgesics like morphine or fentanyl are the most widely used medicines for relieving severe acute or chronic pain, including cancer pain. Unfortunately, chronic pain treatment is associated with fast development of tolerance that creates the need to escalate the treatment doses. In addition, opiates may stimulate progression of cancer. Therefore, a new type of effective analgesic especially designed for chronic cancer pain treatment is needed. In this paper, a new opioid peptide analogue has been described as a new analgesic. The compound is characterized by very high agonist affinities to MOR and also high, but ten times lower affinity to DOR. Affinity to hNK1 as an antagonist is on the level of C-terminal hexapeptide fragment analogue of Substance P. The compound expressed reasonable antiproliferative properties toward various cancer cells. Interestingly, the peptide did not interfere with the proliferation of fibroblasts. Therefore, the compound should be considered as a new analgesic for treatment of cancer-related pains with adjuvant anticancer properties which may support cancer treatments.

keywords:

Original articleOpioid agonist – tachykinin antagonist as a new analgesic with adjuvant anticancer properties

Joanna Matalińska , Henryk Skurzak , Sergiusz Markowicz , Anna Lesniak , Mariusz Sacharczuk , Gabriella Molnar , Eva Varga , Andrzej W. Lipkowski

opioid peptide analogue, analgesics, cancer, neurokinin antagonist

Original article
Opioid agonist – tachykinin antagonist as a new analgesic with adjuvant anticancer properties

Joanna Matalińska

,

Henryk Skurzak

,

Sergiusz Markowicz

,

Anna Lesniak

,

Mariusz Sacharczuk

,

Gabriella Molnar

,

Eva Varga

,

Andrzej W. Lipkowski